Business Context and Reporting Period
This Form 8-K is a current report filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on June 14, 2023. The filing documents the results of the Company's 2023 Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
The primary material event reported is the approval of the Amended and Restated 2015 Employee Stock Purchase Plan (A&R ESPP). Key terms of the approved plan include:
- Reservation of an additional 125,000 shares of common stock for issuance.
- Extension of the automatic annual share reserve increase feature until January 1, 2028.
- Increase in the automatic annual share reserve size to the lesser of 2% of outstanding shares or 75,000 shares.
Stockholder Vote Results
Four proposals were submitted to stockholders. The voting results were as follows:
| Proposal | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Class II Directors (3 nominees) | 267,578 - 270,248 | 547 - 641 | 43,593 - 46,254 | 727,170 |
| Approval of A&R ESPP | 224,289 | 74,630 | 15,554 | 727,170 |
| Advisory Vote on Executive Compensation | 216,044 | 85,774 | 12,655 | 727,170 |
| Ratification of Ernst & Young LLP | 913,353 | 103,072 | 25,218 | N/A |
Outlook, Risks, and Management Commentary
The filing contains no management commentary regarding business outlook, risks, contingencies, or unusual items. It strictly reports the procedural outcomes of the Annual Meeting.
Key Facts for Investor Verification
- Verify the company name is Salarius Pharmaceuticals, Inc. (SLRX), as the input metadata incorrectly referenced Decoy Therapeutics Inc.
- Confirm the ESPP share reserve increase of 125,000 shares and the new annual increase cap of 75,000 shares.
- Note the significant number of Broker Non-Votes (727,170) on director elections and the ESPP proposal, indicating a large portion of shares held in street name did not receive voting instructions.
- Review the Proxy Statement filed on May 1, 2023, for detailed terms of the ESPP and executive compensation.